Abstract
The aim of our paper is to evaluate treatment results for WHO grade III gliomas in the Czech Republic. We performed an assessment of a sample of patients from the glioma tumor DoIT registry.
Data on 226 patients dia-gnosed with WHO grade III gliomas between 1 January 2007 and 31 December 2012 in ten centers were available for statistical analysis. We failed to prove an effect of gender on overall survival.
However, a positive effect of patient age, oligodendroglial tumor component (median survival - 45.3 months), extent of resection (median survival - 25.4 months), chemoradiotherapy vs. radiotherapy alone (median survival - 33.1 vs. 11.6 months) was shown as well as a synergic effect of total tumor resection plus chemoradiotherapy on overall survival (median survival - 36 months). Temozolomide was the first-choice chemotherapy regimen in all centers; PCV chemotherapy was initially administered in one case of oligo-glioma only.
The analysis also implies that implementation of cytogenetic investigation of prognostic markers (MGMT, 1p/19q, IDH, ATRX) into standard laboratory procedures is required if individualized therapy of WHO grade III glioma is to take place. WHO grade III gliomas are a very heterogeneous group of tumors with different prognosis and treatment response.
Virtually all comprehensive cancer centers have appointed neuro-oncologic teams including neurologists and neurosurgeons who thus participate in establishing the general management strategy for WHO grade III gliomas. Key words: anaplastic gliomas - general management strategy - radical resection - chemoradiotherapy The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.
The Editorial Board declares that the manu-script met the ICMJE "uniform requirements" for biomedical papers.